ENGN advances detalimogene voraplasmid toward pivotal data and FDA filing
ENGN’s detalimogene voraplasmid, a non-viral gene therapy for BCG-unresponsive NMIBC, is nearing pivotal data and an FDA filing expected by year-end, with interim efficacy and tolerability cited as strong.
Detalimogene voraplasmid, a non-viral gene therapy for BCG-unresponsive NMIBC, is advancing toward pivotal data readout and FDA filing by year-end, with strong interim efficacy and best-in-class tolerability. The therapy is positioned for broad adoption in community practices, with future enhanceme…